L. Goldstein
Journal of Clinical Oncology · 2002–2022
A researcher in the Science corpus: 7 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Papers from L. Goldstein's perspective
Ordered by how strongly the researchers L. Goldstein trusts endorse each paper. Same corpus, a different order for every researcher.
- Reporting recommendations for tumor marker prognostic studies. (Journal of Clinical Oncology)
- Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to… (Journal of Clinical Oncology)
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Archives of Pathology & Laboratory Medicine)
- Weekly paclitaxel in the adjuvant treatment of breast cancer. (New England Journal of Medicine)
- Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. (Journal of Clinical Oncology)
- Modeling Survival Data Extending The Cox Model
- A gene-expression signature as a predictor of survival in breast cancer. (New England Journal of Medicine)
- Lymphatic mapping and sentinel lymphadenectomy for breast cancer. (American Journal of Surgery)
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome (Science)
- PD-1 blockade induces responses by inhibiting adaptive immune resistance (Nature)
Their papers
- Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. (2022) — 775 citations
- 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer (2021) — 692 citations
- Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. (2020) — 884 citations
- Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. (2014) — 1,170 citations
- Prognostic and predictive factors in early-stage breast cancer. (2004) — 671 citations
- Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. (2003) — 1,318 citations
- American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. (2002) — 1,010 citations